# Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care

> **NCT03425773** · PHASE1 · COMPLETED · sponsor: **Cellid Co., Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **BIOLOGICAL:** BVAC-B

## Key facts

- **NCT ID:** NCT03425773
- **Lead sponsor:** Cellid Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-26
- **Primary completion:** 2019-05-13
- **Final completion:** 2019-05-13
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03425773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03425773, "Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03425773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*